Corline Biomedical AB
SSE:CLBIO.ST
13.8 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 25.03 | 23.55 | 7.062 | 3.696 | 1.064 | 1.563 | 0.638 | 0.947 | 1.037 | 1.683 | 1.788 | 5.999 |
| Cost of Revenue
| -3.35 | 0.824 | -2.04 | -6.624 | -6.083 | -4.966 | -0.033 | -6.503 | -2.164 | -1.707 | -2.239 | 0.135 |
| Gross Profit
| 28.38 | 22.726 | 9.102 | 10.32 | 7.147 | 6.529 | 0.671 | 7.45 | 3.201 | 3.391 | 4.027 | 5.864 |
| Gross Profit Ratio
| 1.134 | 0.965 | 1.289 | 2.792 | 6.717 | 4.177 | 1.052 | 7.867 | 3.086 | 2.014 | 2.253 | 0.977 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 6.218 | 3.421 | 5.449 | 11.944 | 6.915 | 2.537 | 1.422 | 1.827 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 13.27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 28.742 | 20.89 | 15.949 | 6.218 | 16.691 | 5.449 | 11.944 | 6.915 | 2.537 | 1.422 | 1.827 | 6.672 |
| Other Expenses
| 30.168 | 20.397 | 11.135 | 11.389 | 16.687 | 7.872 | -3.465 | 5.755 | 6.312 | 4.47 | 4.617 | 0 |
| Operating Expenses
| 30.168 | 20.397 | 11.135 | 17.607 | 16.687 | 13.321 | 8.479 | 12.67 | 8.849 | 5.892 | 6.444 | 6.698 |
| Operating Income
| -1.788 | 2.329 | -6.909 | -7.287 | -9.54 | -6.792 | -7.809 | -5.22 | -5.676 | -2.502 | -2.417 | -0.833 |
| Operating Income Ratio
| -0.071 | 0.099 | -0.978 | -1.972 | -8.966 | -4.345 | -12.24 | -5.512 | -5.473 | -1.486 | -1.352 | -0.139 |
| Total Other Income Expenses Net
| -1.809 | 0.549 | -0.013 | -0.084 | 0.013 | -0.001 | -0.002 | -0.028 | -0.197 | -0.01 | -0.071 | -0.078 |
| Income Before Tax
| -1.809 | 2.329 | -6.922 | -7.287 | -9.54 | -6.793 | -7.81 | -5.248 | -5.845 | -2.512 | -2.488 | -0.911 |
| Income Before Tax Ratio
| -0.072 | 0.099 | -0.98 | -1.972 | -8.966 | -4.346 | -12.241 | -5.542 | -5.636 | -1.492 | -1.392 | -0.152 |
| Income Tax Expense
| -1.783 | 0.549 | -0.006 | -0.084 | 0.013 | 0.001 | -0.001 | 0 | -0.028 | 0.023 | 0.007 | 0 |
| Net Income
| -1.809 | 2.329 | -6.916 | -7.287 | -9.54 | -6.793 | -7.81 | -5.248 | -5.845 | -2.512 | -2.488 | -0.911 |
| Net Income Ratio
| -0.072 | 0.099 | -0.979 | -1.972 | -8.966 | -4.346 | -12.241 | -5.542 | -5.636 | -1.492 | -1.392 | -0.152 |
| EPS
| -0.084 | 0.11 | -0.34 | -0.42 | -0.57 | -0.44 | -0.59 | -0.43 | -0.68 | -0.38 | -0.37 | -0.136 |
| EPS Diluted
| -0.084 | 0.11 | -0.34 | -0.42 | -0.57 | -0.44 | -0.57 | -0.43 | -0.66 | -0.25 | -0.25 | -0.092 |
| EBITDA
| -1.686 | 2.385 | -6.878 | -7.273 | -9.531 | -6.792 | -7.808 | -5.219 | -5.647 | -2.445 | -2.383 | -0.807 |
| EBITDA Ratio
| -0.067 | 0.101 | -0.974 | -1.968 | -8.958 | -4.345 | -12.238 | -5.511 | -5.445 | -1.452 | -1.333 | -0.135 |